Kringle Pharma, Inc. (TYO:4884)
Japan
· Delayed Price · Currency is JPY 859.00
-19.00 (-2.16%)
Jun 6, 2025, 3:30 PM JST
Kringle Pharma Balance Sheet
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2018 - 2019 |
| Cash & Equivalents | 1,886 | 2,313 | 2,136 | 2,756 | 2,137 | 2,102 | Upgrade
|
| Cash & Short-Term Investments | 1,886 | 2,313 | 2,136 | 2,756 | 2,137 | 2,102 | Upgrade
|
| Cash Growth | -24.23% | 8.29% | -22.50% | 28.97% | 1.67% | 1166.26% | Upgrade
|
| Accounts Receivable | - | - | 7 | - | 6 | 105 | Upgrade
|
| Other Receivables | 33 | 57 | 74 | 67 | 76 | 23 | Upgrade
|
| Receivables | 33 | 57 | 81 | 67 | 82 | 128 | Upgrade
|
| Inventory | 250 | 294 | 364 | 349 | 315 | 46 | Upgrade
|
| Prepaid Expenses | - | 23 | 14 | 11 | 12 | 4 | Upgrade
|
| Other Current Assets | 96 | 68 | 22 | 24 | 88 | 69 | Upgrade
|
| Total Current Assets | 2,265 | 2,755 | 2,617 | 3,207 | 2,634 | 2,349 | Upgrade
|
| Long-Term Investments | 24 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Other Long-Term Assets | 1 | 1 | - | - | - | - | Upgrade
|
| Total Assets | 2,290 | 2,757 | 2,618 | 3,208 | 2,635 | 2,350 | Upgrade
|
| Accounts Payable | - | 1 | - | 1 | - | - | Upgrade
|
| Accrued Expenses | - | 21 | 5 | 2 | 3 | 2 | Upgrade
|
| Current Income Taxes Payable | 109 | 37 | 173 | 54 | 32 | 74 | Upgrade
|
| Other Current Liabilities | 46 | 69 | 31 | 105 | 92 | 83 | Upgrade
|
| Total Current Liabilities | 155 | 128 | 209 | 162 | 127 | 159 | Upgrade
|
| Other Long-Term Liabilities | 527 | 522 | 388 | 258 | 2 | 3 | Upgrade
|
| Total Liabilities | 682 | 650 | 597 | 420 | 129 | 162 | Upgrade
|
| Common Stock | 12 | 11 | 97 | 59 | 51 | 300 | Upgrade
|
| Additional Paid-In Capital | 2,841 | 2,835 | 3,095 | 3,057 | 2,755 | 2,654 | Upgrade
|
| Retained Earnings | -1,268 | -756 | -1,185 | -331 | -301 | -765 | Upgrade
|
| Comprehensive Income & Other | 23 | 17 | 14 | 3 | 1 | -1 | Upgrade
|
| Shareholders' Equity | 1,608 | 2,107 | 2,021 | 2,788 | 2,506 | 2,188 | Upgrade
|
| Total Liabilities & Equity | 2,290 | 2,757 | 2,618 | 3,208 | 2,635 | 2,350 | Upgrade
|
| Net Cash (Debt) | 1,886 | 2,313 | 2,136 | 2,756 | 2,137 | 2,102 | Upgrade
|
| Net Cash Growth | -24.23% | 8.29% | -22.50% | 28.97% | 1.67% | 1166.26% | Upgrade
|
| Net Cash Per Share | 278.68 | 361.45 | 396.27 | 567.55 | 514.49 | 38068.68 | Upgrade
|
| Filing Date Shares Outstanding | 6.84 | 6.81 | 5.41 | 5.38 | 4.33 | 1.29 | Upgrade
|
| Total Common Shares Outstanding | 6.84 | 6.81 | 5.41 | 5.38 | 4.33 | 1.29 | Upgrade
|
| Working Capital | 2,110 | 2,627 | 2,408 | 3,045 | 2,507 | 2,190 | Upgrade
|
| Book Value Per Share | 235.19 | 309.37 | 373.88 | 518.16 | 578.13 | 1690.75 | Upgrade
|
| Tangible Book Value | 1,608 | 2,107 | 2,021 | 2,788 | 2,506 | 2,188 | Upgrade
|
| Tangible Book Value Per Share | 235.19 | 309.37 | 373.88 | 518.16 | 578.13 | 1690.75 | Upgrade
|
Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.